Collecting Patient Feedback on Cancer Treatment Using Online Surveys
A Randomized Clinical Trial of Electronic Tumour-Specific Patient-Reported Outcomes in Early-Stage Breast and Colorectal Cancer Patients Undergoing Neoadjuvant/Adjuvant Chemotherapy
This study is testing if using online surveys to track symptoms can help improve care for patients with early-stage breast and colorectal cancer during their treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 128 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | AHS Cancer Control Alberta Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Calgary, Alberta) |
| Trial ID | NCT04990895 on ClinicalTrials.gov |
What this trial studies
This clinical trial compares the effectiveness of electronic patient-reported outcomes (ePROs) with targeted symptom management against standard follow-up care for patients undergoing neoadjuvant or adjuvant systemic therapy for early-stage breast and colorectal cancer. Participants will use a web-based portal to regularly report their health-related quality of life and symptoms throughout their treatment. The study aims to identify patients experiencing significant symptoms and provide timely interventions through nurse assessments. By leveraging technology, the trial seeks to enhance patient care and symptom management during cancer treatment.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with newly diagnosed early-stage breast or colorectal cancer who are starting neoadjuvant or adjuvant systemic therapy.
Not a fit: Patients who are not fluent in English, lack internet access, or are not receiving chemotherapy will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved symptom management and quality of life for cancer patients during treatment.
How similar studies have performed: Other studies utilizing electronic patient-reported outcomes have shown promise in improving patient care, suggesting that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Participant has provided informed consent prior to initiation of any study specific activities/procedures. 2. Men or women ≥18 years old newly diagnosed early stage (stage I, II, or III) breast or colorectal cancer who initiate neoadjuvant/adjuvant systemic therapy after curative intent surgery. 3. Participants or their caregivers will need to have a computer and internet access at home and be willing to learn to use and enter data via the web-based portal (REDCap). 4. For the purposes of the current study, fluency and literacy in English will be required. Exclusion Criteria: 1. Lack of fluency or literacy of the English language. 2. Lack of access to a computer or internet at home. 3. Inability to complete or enter data on the REDCap system. 4. Early-stage breast or colorectal cancer patients who are not receiving neoadjuvant/adjuvant chemotherapy (patients undergoing adjuvant hormonal or targeted therapy alone without chemotherapy will be excluded). 5. Has known psychiatric or substance abuse disorders that would interfere with compliance with the requirements of the trial.
Where this trial is running
Calgary, Alberta
- Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta, Canada (Recruiting)
Study contacts
- Principal investigator: Nancy A Nixon, M.D. — Arthur J.E. Child Comprehensive Cancer Centre
- Study coordinator: Nancy A Nixon, M.D.
- Email: Nancy.A.Nixon@albertahealthservices.ca
- Phone: +1 (403) 521-3912
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.